Ram Mandalam, President & CEO
Richard Chyette, Corporate Counsel/Secretary, Quicken Loans Inc.; Advisor, Camelot Ventures LLC
Steve Greenberg, Managing Director, Allen & Company LLC
Richard G. Rathmann, Manager of GBR Investments
Gisela M. Schwab, EVP and Chief Medical Officer, Exelixis
Lowell E. Sears, Chairman and CEO, Sears Capital Management
Ram Mandalam, Ph.D., our President & CEO, joined the company in 2005. Ram was previously Executive Director of Product Development at Geron Corporation, where he managed the development and manufacturing of cell based therapies for treatment of degenerative diseases and cancer. Prior to Geron, he was Director of Developmental Research at Aastrom Biosciences, where he was responsible for the research and development programs involving ex vivo expansion of human bone marrow stem cells and dendritic cells. Dr. Mandalam received his Ph.D. in Chemical Engineering from the University of Michigan. Dr. Mandalam is the author or co-author of several publications, patent applications, and abstracts.
Richard Chyette is Corporate Counsel and Corporate Secretary to Quicken Loans Inc., the nation's largest on-line residential mortgage lender and the 15th largest retail mortgage lender overall. He has been a member of the company's senior leadership team since 1993 and is an officer of the company's holding company, Rock Holdings Inc. Mr. Chyette holds a law degree from Wayne State University and a Masters degree in Labor and Industrial Relations from Michigan State University, where he also completed his undergraduate studies. Mr. Chyette is an advisor to Daniel Gilbert (the founder and current chairman of Quicken Loans who is also a majority owner of the Cleveland Cavaliers) with respect to various business ventures and real estate transactions, and is an advisor to Camelot Ventures, a venture capital firm headed by Mr. Gilbert.
Steve Greenberg has been a managing director of Allen & Company LLC since January 2002. At Allen & Company, he is part of the firm's investment banking group. Immediately prior to joining Allen & Company, Mr. Greenberg was the Co-founder and Chairman of Fusient Media Ventures, a New York-based sports and media company. Prior to starting Fusient, Mr. Greenberg co-founded Classic Sports Network in 1993 and served as its president until the network was sold to ESPN in 1997. From 1990 to 1993, Mr. Greenberg served as the Deputy Commissioner and Chief Operating Officer of Major League Baseball under Commissioner. At MLB, Mr. Greenberg oversaw the day-to-day operations of the Commissioner's office, including Broadcasting, Finance, Legal, Baseball Operations, Special Events and the League's lucrative properties licensing operation. Prior to MLB, Mr. Greenberg practiced law from 1977 through the end of 1989 with the Los Angeles firm of Manatt, Phelps & Phillips where he specialized in Sports and General Business Law and served as the firm's managing partner in 1987 and 1988. Mr. Greenberg earned his B.A. at Yale University in 1970 and subsequently received his J.D. degree from the UCLA Law School in 1977. Mr. Greenberg currently serves on the Board of Directors of The Topps Company (Nasdaq – TOPP) and Convera Corporation (Nasdaq – CNVR).
Richard G. Rathmann, is the Manager of GBR Investments, LLC, (the private investment fund of George B. Rathmann, cofounder of Amgen, ICOS). Mr. Rathmann also serves as the Executive Director of the Rathmann Family Foundation. Previously, Mr. Rathmann co-managed the seed and early stage venture fund Falcon Technology Partners, L.P. (Adolor, Caliper, Ciphergen/Vermillion, Decode, Genomica). Over the past 16 years, Mr. Rathmann has held observer rights or board positions on several biotechnology and non-profit organizations including most recently NaniRx Therapeutics and the National Science and Technology Medals Foundation. Mr. Rathmann received his B.A. from the University of Colorado and his J.D. degree from Boston College Law School. A former Assistant United States Attorney in the Central District of California (Los Angeles), Mr. Rathmann currently serves on the Board of Directors of the Rathmann Family Foundation and Cellerant Therapeutics.
Gisela M. Schwab, M.D., currently serves as Executive Vice President and Chief Medical Officer of Exelixis. Previously, she held the position of Senior Vice President and Chief Medical Officer at Abgenix, Inc., a human antibody-based drug development company. Prior to Abgenix, Dr. Schwab held positions of increasing responsibility at Amgen Inc., most recently as Director of Clinical Research and Hematology/Oncology Therapeutic Area Team Leader. Dr. Schwab also serves as a member of the board of directors of Topotarget A/S, a publicly-held biopharmaceutical company. She received her Doctor of Medicine degree from the University of Heidelberg, trained at the University of Erlangen-Nuremberg and the National Cancer Institute and is board certified in internal medicine and hematology and oncology.
Lowell E. Sears, Chairman, is the Chairman and CEO of Sears Capital Management, a venture investment and portfolio management firm specializing in life sciences. He has been an active life science venture investor since 1994, helping to found and fund over forty companies. From 1986 until 1994, Mr. Sears was a part of the senior management team of Amgen, Inc., where he held positions of Chief Financial Officer as well as Senior Vice President responsible for the Asia Pacific Region. Prior to joining to Amgen, Mr. Sears held senior planning and financial positions with Atlantic Richfield Company (ARCO) from 1976 until 1986, including a period as Chief Financial Officer for its Ventures Division. Mr. Sears has served on twenty boards of directors, including roles as board chairman and audit committee chair. He currently serves on the board of SymBio Pharmaceuticals, KK, Ltd. (JASDAQ: 4582).